-

09:48:45 PM

NRSN Stock News

NRSN - NeuroSense Therapeutics Ltd

12/01/22 9:05 AM

Nasdaq : NRSN

earningslow float

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update."During

RHEA-AI

neutral

11/16/22 9:34 AM

Nasdaq : NRSN

clinical triallow float

NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in

RHEA-AI

neutral

11/15/22 8:30 AM

Nasdaq : NRSN

clinical triallow float

NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study

RHEA-AI

very positive

10/27/22 8:50 AM

Nasdaq : NRSN

conferenceslow float

NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.Conference: The 21st Annual NEALS MeetingDr. Ferenc

RHEA-AI

neutral

10/21/22 9:25 AM

Nasdaq : NRSN

conferenceslow float

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing,

RHEA-AI

neutral

10/18/22 8:33 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of

RHEA-AI

very positive

10/12/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced

RHEA-AI

positive

09/29/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative

RHEA-AI

neutral

09/28/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for

RHEA-AI

very positive

09/21/22 8:51 AM

Nasdaq : NRSN

conferenceslow float

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)

RHEA-AI

neutral

NRSN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.neurosense-tx.com
Security nameNeuroSense Therapeutics Ltd
Issue typecs
SectorManufacturing
Sic code2834

About NeuroSense Therapeutics Ltd

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient. During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense. To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases. NeuroSense is focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases. Its research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve its goals. NeuroSense is currently preparing for a phase 2b/3 clinical trial using PrimeC in patients with ALS. NeuroSense is also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. Additionally, NeuroSense is studying the mechanisms of action and relevant biomarkers for these diseases.